Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06962670 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Predicting Cancer Risk With Digital and Molecular Markers

Study acronym: PräDigt
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 8, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The goal of this study is to identify new markers to predict the risk of developing cancer, primarily breast cancer. For this purpose, researchers will compare data obtained from cancer patients and healthy individuals. If characteristic differences are identified, e.g. in biomarkers, life style or family history, this may indicate a person's increased risk of developing cancer.
Trial Details
NCT Number NCT06962670
Lead Sponsor University of Erlangen-Nürnberg Medical School
Conditions
(from sponsor)		 Breast Cancer, Lung Cancer, Colorectal Cancer, Gynecologic Cancer
Related terms Breast Neoplasms, Colorectal Neoplasms, Lung Neoplasms
Enrollment 1,250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov